Imugene Ltd
Imugene Ltd (ASX:IMU) is listed on the Australian Securities Exchange.
See more information about Imugene Ltd
Imugene director increases stake, capital raising underway
Imugene Ltd (ASX:IMU) non-executive director Paul Hopper has increased his shareholding in the company substantially.
He recently acquired 100.9 million shares increasing his overall holding to 177.1 million shares, more than doubling his stake.
Shares in the company entered a trading halt yesterday pending the release of details regarding a capital raising.
Industry sources suggest Imugene is raising up to $24.6 million through a placement priced at 3.6 cents with attaching options.
The raising is being led by brokers Bell Potter and Aurenda Partners.
Imugene is a clinical-stage biotech company developing a range of immunotherapies that seek to activate the immune system of cancer patients to treat tumors.
Other Imugene Ltd news
- Imugene outlines its focus on developing immuno-oncology treatments in half-yearly report
2020-02-28 - Imugene has CheckVacc preclinical data published in the Journal of American College of Surgeons
2020-02-12 - Imugene appoints surgeon-scientist Dr Rebecca Auer to oncolytic virotherapy advisory board
2019-12-05 - Imugene plans two separate phase I clinical trials for CF33 oncolytic virus
2019-11-25 - Imugene appoints distinguished physician and scientist to the Scientific Advisory Board
2019-11-20
